Gene expression markers of Tumor Infiltrating Leukocytes.
Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. · 2017
Read Gene expression markers of Tumor Infiltrating Leukocytes. by Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5319024.txt.
Introduction
Patrick Danaher and co-authors built a gene test for immune cells in tumors, in the Journal for Immunotherapy of Cancer in 2017. The mix of immune cells inside a tumor can guide cancer care and drug choice. Gene tests can read that mix from a small tissue sample in a routine lab flow. Past lists of marker genes were built from pure cells, though, and many fail in real tumors.
The team checked old marker lists against gene patterns in close to ten thousand tumor samples. Shared patterns exposed false markers, which they cut. Sixty strong marker genes remained, enough to score fourteen immune cell types. Scores from the genes matched cell counts from standard lab methods. Repeated runs on stored tumor tissue gave steady results. The set gives labs a firm tool for reading tumor immune mixes.
Catalog record
| CREATOR | Danaher P, Warren S, Dennis L, D'Amico L, White A, Disis ML, Geller MA, Odunsi K, Beechem J, Fling SP. |
|---|---|
| YEAR | 2017 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Gene expression markers of Tumor Infiltrating Leukocytes By Patrick Danaher, Sarah Warren, Lucas Dennis, Leonard D’Amico, Andrew White, Mary L Disis, Melissa A Geller, Kunle Odunsi, Joseph Beechem, Steven P Fling Published in: Journal for Immunotherapy of Cancer DOI: 10.1186/s40425-017-0215-8 ABSTRACT Abstract Background Assays of the abundance of immune cell populations in the tumor microenvironment promise to inform immune oncology research and the choice of immunotherapy for individual patients. We propose to measure the intratumoral abundance of various immune cell populations with gene expression. In contrast to IHC and flow cytometry, gene expression assays yield high information content from a clinically practical workflow. Previous studies of gene expression in purified immune cells have reported hundreds of genes showing enrichment in a single cell type, but the utility of these genes in tumor samples is unknown. We use co-expression patterns in large tumor gene expression datasets to evaluate previously reported candidate cell type marker genes lists, eliminate numerous false positives and identify a subset of high confidence marker genes. Methods Using a novel statistical tool, we use co-expression patterns in 9986 samples from The Cancer Genome Atlas (TCGA) to evaluate previously reported cell type marker genes. We compare immune cell scores derived from these genes to measurements from flow cytometry and immunohistochemistry. We characterize the reproducibility of our cell scores in replicate runs of RNA extracted from FFPE tumor tissue. Results We identify a list of 60 marker genes whose expression levels measure 14 immune cell populations. Cell type scores calculated from these genes are concordant with flow cytometry and IHC readings, show high reproducibility in replicate RNA samples from FFPE tissue and enable detailed analyses of the anti-tumor immune response in TCGA. In an immunotherapy dataset, they separate responders and non-responders early on therapy and provide an intricate picture of the effects of checkpoint inhibition. Most genes previously reported to be enriched in a single cell type have co-expression patterns inconsistent with cell type specificity. Conclusions Due to their concise gene set, computational simplicity and utility in tumor samples, these cell type gene signatures may be useful in future discovery research and clinical trials to understand how tumors and therapeutic intervention shape the immune response. Electronic supplementary material The online version of this article (doi:10.1186/s40425-017-0215-8) contains supplementary material, which is available to authorized users. Keywords: Gene expression, Tumor infiltrating lymphocytes, Immunotherapies, TILs, Cell types BACKGROUND The abundance and composition of the immune cells infiltrating a tumor predict both a patient’s prognosis [1–5] and the optimal immunotherapy for their disease [6]. Therefore techniques to profile tumor infiltrating lymphocytes (TILs) in a clinical setting are needed. While flow cytometry is the current gold standard for quantifying immune cell populations, sample and/or workflow constraints make it infeasible in many research and clinical applications, especially those utilizing FFPE tissue. Immunohistochemistry (IHC) has been shown to be clinically useful [2], but it cannot assay more than a few immune markers without using up excessive tissue. In contrast to these older technologies, gene expression profiling promises a clinically practical way to measure the full diversity of the tumor immune infiltrate in settings and sample types where flow cytometry is unworkable, additionally allowing the simultaneous measurement of hundreds to thousands of other relevant genes. Therefore, we propose to identify genes whose expression levels can be used to measure the abundance of various immune cell populations within the tumor microenvironment. Previous authors have identified genes specific to purified immune cell populations [7–9] and used these genes to quantify immune populations in tumors [9, 10]. However, these genes were discovered using purified cells and not immune cells taken from the tumor microenvironment, and so any differences between intratumoral and in vitro gene expression patterns will compromise their utility in tumor samples. To address this concern, we propose a novel computational method for testing whether previously reported cell type marker genes are useful in tumor data. We then apply this method to data from The Cancer Genome Atlas (TCGA) to derive a set of 60 marker genes for 14 immune cell populations. Our final gene list exhibits sufficiently strong cell type specificity to allow measurement of immune cell populations with scores computed as the simple average log expression of their marker genes. In data from ovarian cancer patients, these cell type scores are concordant with both immunohistochemistry (IHC) and flow cytometry. In replicate RNA samples, they display substantially better reproducibility than typical IHC readings. In TCGA data, they enable detailed analyses of anti-tumoral immunity. In an immunotherapy dataset, they provide early discrimination between responders and non-responders and reveal an intricate picture of the immune response to checkpoint inhibition. Due to their concise gene set, computational simplicity and utility in tumor samples, these cell type gene signatures may be useful in future discovery research and clinical trials to understand how tumors and therapeutic intervention shape the immune response. METHODS Derivation of candidate cell type marker genes from the literature The first step in our marker gene identification process is to identify previously reported cell type markers. Fortunately, the literature is rich in papers measuring gene expression in isolated immune cell populations. A number of authors, most notably [7] and [9], have used meta-analyses of these experiments to discover genes that are predominantly expressed within a single immune cell population. Our list of candidate marker genes is primarily drawn from [7], whose cell type-specific gene lists we took verbatim as the foundation of our candidate markers list. To derive candidate markers for cell types missing in [7], we took genes that [9] reported to be highly enriched in one cell type vs. the maximum seen in all other cell types. We also included well-known markers for exhausted CD8 cells [11–13] and FOXP3 for Tregs. Our full list of candidate marker genes can be found in Additional file 1: Table S3. Approach to evaluation of candidate cell type marker genes in tumor gene expression data The literature on cell type specific gene expression is a powerful source of candidate marker genes, but there are a variety of mechanisms by which poor marker genes may have entered the literature. First, early microarray studies were frequently underpowered, noisy and rife with batch effects and therefore could indicate spurious marker genes [14]. Second, and very significantly, the expression profile of in vitro purified cells may differ substantially from these cells’ gene expression in the tumor microenvironment [15]. Finally, genes that appear specific to one cell type in a microarray experiment may be expressed in cell types omitted from the experiment. Therefore, our literature-derived candidate marker genes require validation in actual tumor expression data. Ideally, we would test whether each gene displays two properties: expression specific to a single cell type, and stable expression within that cell type. Unfortunately, we cannot directly measure a gene’s adherence to these properties in bulk tumor expression data; instead, we look for genes whose expression patterns are consistent with these properties. If two genes are both ideal markers, expressed with perfect specificity to and stability within a cell type, their expression levels will be perfectly correlated, and the ratio between them will be constant across samples. Figure 1 demonstrates this principle. Of the 4 candidate marker genes for a cell population,